RECRUITING

IO vs IV Vancomycin in Tourniquetless TKA

Talk to us

Conditions

Infection, Surgical SiteVancomycinTotal Knee ArthroplastyTourniquetless

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Purpose of this study is to compare the efficacy of intravenous and intraosseous antibiotic administration techniques during tourniquetless total knee arthroplasty.

Official Title

Intraosseous Vancomycin vs Intravenous Vancomycin in Tourniquetless Primary Total Knee Arthroplasty

Quick Facts

Study Start:2023-01-25
Study Completion:2024-01-25
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05705843

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:19 Years to 80 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Patient is undergoing a primary total knee arthroplasty.
  2. * Patient is able to understand the study design and intervention and gives informed consent to participate in the study. No LAR consents will be utilized for this study.
  3. * Age \>18 years.
  4. * Total knee arthroplasty performed without the use of a tourniquet.
  1. * Previous surgery on the knee (including arthroscopic knee surgery)
  2. * BMI above 35
  3. * Contraindication to receiving vancomycin, cefepime, ancef, or other standard of care pre-operative antibiotic (allergy, medical issue, etc).
  4. * Inability to locate the tibial tubercle or administer the IO infusion
  5. * Refusal to participate
  6. * Uncontrolled Diabetes Mellitus type 1 or 2, defined as Hemoglobin A1C \>7.5.
  7. * Immunocompromised or immunosuppressed patients (HIV, Hep C, End-Stage Renal Disease, dialysis, transplant, chemo/radiation treatment in last 6 months, and immunosuppresive medications)

Contacts and Locations

Study Contact

Thomas C Sullivan, BS
CONTACT
346-238-1603
tsullivan@houstonmethodist.org
Haley Goble, MHA
CONTACT
7134413930
hmgoble@houstonmethodist.org

Study Locations (Sites)

Houston Methodist Hospital Outpatient Center
Houston, Texas, 77030
United States

Collaborators and Investigators

Sponsor: The Methodist Hospital Research Institute

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-01-25
Study Completion Date2024-01-25

Study Record Updates

Study Start Date2023-01-25
Study Completion Date2024-01-25

Terms related to this study

Keywords Provided by Researchers

  • Vancomycin
  • Total Knee Arthroplasty
  • Tourniquetless

Additional Relevant MeSH Terms

  • Infection, Surgical Site